PAT & QbD brochure (PDF) - JMP

Presents the 7th Annual
PAT and Quality
SAVE up
to £300
register and pay by
30th October 2009
by Design
Two-Day Conference: 19th-20th January 2010
Pre-Conference Workshops: 18th January 2010
Grand Connaught Rooms, London
Drive efficiency and take that next step by establishing a successful
PAT and Quality by Design strategy for your entire business
Establish a successful change management
strategy when implementing QbD across the
whole business: Novo Nordisk discuss
their strategy and how it’s helping them create a
smoother transition
Effectively apply PAT and QbD principles to
Biopharmaceuticals: Eli Lilly discuss the
outcomes of an industry consortium with
guidance from the FDA
Cut a clear path to regulatory submission
success: Bristol Myers Squibb discuss how
they succeeded in their QbD submission and
how you can do the same
Capture and manipulate real time data
efficiently to support your PAT/QbD initiatives:
Vertex Pharmaceuticals share their recent
experiences and show you get the most out of
your data
Pre-Conference Workshops
A Application of PAT and QbD for
Biopharmaceuticals
B De-mystifying Regulatory Submission
for PAT and QbD
www.patandqbd.com
Expert speakers include:
KEYNOTE SPEAKER
Dr Victor A. Vinci, Director, Bioprocess Operations,
Eli Lilly and Company
≥Key Regulatory Insight: Des Makohon, Senior GMP
Inspector, MHRA. Member, PAT Team, EMEA
≥Gerald DiDonato, Group Director, Global Regulatory
Sciences CMC,Bristol Myers Squibb
≥Michael Schousboe, Expert, Manufacturing Science and
Quality, Novo Nordisk
≥Martin Warman, Scientific Fellow, Analytical Development,
Vertex Pharmaceuticals
≥David Sharp, Senior Principal Scientist, Pfizer
≥Hans ter Maat, Senior Process Engineer, DSM Biologics
≥Zadeo Cimarosti, Manager, Chemical Development,
GlaxoSmithKline Verona Italy
≥Philippe Cappuyns, Pharmaceutical Technology Director,
Janssen Pharmaceutica
≥Dr Hedinn Valthorsson, Manufacturing Manager, Novartis
≥Dr Barry Gujral MBA, Associate Director, Quality
Engineering, Noven Pharmaceuticals Inc.
≥Ayub Khan, Senior Process Technologist, Napp
Pharmaceuticals
≥Branko Vranic, PhD Student and Teaching Assistant,
Industrial Pharmacy Lab, University of Basel
≥Professor Julian Morris, Technical Director, CPACT
≥Petter Morree, Director, Online Products, Umetrics AB
≥Peter Amanatides, Vice President QA and QC, Noven
Pharmaceuticals Inc.
≥Martin Owen, Manager, GlaxoSmithKline UK
≥Dr Per Vase, Senior Specialist, Consulting, NNE Pharmaplan
≥Patrick Bossuyt, SIPAT Sales Executive, SIEMENS
Session
Sponsors
Gold
Exhibitor
Media
Partners
CALL: +44 (0)20 7368 9300 / 0800 652 2363 FAX: +44 (0)20 7368 9301 EMAIL: enquire@iqpc.co.uk

Pre-Conference Workshops: 18th January 2010
Workshop A: 10.00-13.00
Application of PAT and QbD for Biopharmaceuticals
With PAT and QbD having a more established hold within the small molecules arena the focus is now turning towards the
more complex Biopharmaceutical sector. This interactive workshop will discuss the different stages and important
considerations focusing on the practical application of PAT and QbD principles for drug design and manufacture. Attendees
will have the chance to discuss case study examples as well as work within smaller groups for more targeted discussions.
Workshop Leader: Dr Victor A. Vinci, Director, Bioprocess Operations, Eli Lilly and Company
Meet your workshop leader
Dr. Vinci is currently Director of Bioprocess Operations at Eli Lilly and Company in Indianapolis, Indiana. As such,
he is responsible for process operations focused on bringing new protein therapeutics to market by producing
active pharmaceutical ingredients intended for clinical trials. For the last 4 years, his responsibilities have
included coordination of teams involved in the design, commissioning and qualification of a new 200,000 sq ft
cGMP bulk process facility, developing staffing models, and implementing effective and compliant operational
practices. His team is currently engaged in tech transfer for new campaigns, bioprocess operations to produce
bulk biologic API, and improving platform operations for bioproducts. He serves as the lead for the Lilly team involved with
the CMC Biotech Working Group (industry consortium) which has finished a QbD case study for a monoclonal antibody (Mab).
Prior to his current role, he was a scientist and group leader in process development at Eli Lilly for five years. He began his
career at Merck where he was a scientist and later section head in an Manufacturing Science and Technology (MS&T) role.
Dr. Vinci received his doctorate in Microbiology from The Ohio State University in 1988.
Workshop B: 14.00-17.00
De-mystifying Regulatory Submission for PAT and QbD
This interactive workshop will allow you to assess successful and unsuccessful FDA and EMEA submissions as well as
giving attendees the opportunity to discuss openly their own experiences and gather fresh ideas on how they can change
their approach for the better.
Workshop Leader: Gerald DiDonato, Associate Director, Global Regulatory Sciences CMC, Bristol Myers Squibb
Meet your workshop leader
Gerald DiDonato, Associate Director, Global Regulatory Sciences-CMC, received his PhD in Analytical Chemistry with a
specialty in mass spectrometery from Indiana University in 1987. Gerald joined Bristol-Myers Squibb as a Research
Investigator solving structure elucidation problems for Discovery, Development and Manufacturing colleagues. He was one
of the first to use electrospray mass spectrometry as a routine structure elucidation tool in the Pharmaceutical Industry.
Subsequently he managed multidisciplinary analytical groups, and led Development and Manufacturing Teams for new
products. Gerald recently chaired the Company's Specification Committee. He saw the light and switched to Regulatory
Affairs in 2005, where he currently is the CMC lead for saxagliptin as well as several products in development.
About Pharma IQ
Become a member of Pharma IQ and receive complimentary access to resources that will
keep you at the forefront of industry change. You will receive access to our growing
library of multi-media presentations from industry leaders, an email newsletter updating
you on new content that has been added, free aggregated news feed from over 1000
global news sources tracking your industry and special member only discounts on events.
Become a member here: Web: www.pharmaceuticaliq.com Phone: +1-646-454-4559
www.patandqbd.com
CALL: +44 (0)20 7368 9300 / 0800 652 2363 FAX: +44 (0)20 7368 9301 EMAIL: enquire@iqpc.co.uk

Conference Day One: 19th January 2010
08.50 Pharma IQ Welcome and Chairperson’s Opening
Address
09.00 Opening Presentation: EU Regulatory
Perspective of PAT Technology and Inspections
Visit www.patandqbd.com for updates
Des Makohon, Senior GMP Inspector, MHRA.
Member, PAT Team, EMEA
09.45 Case Study: Filing a QbD Submission Across the
Globe
• Outline of the product (saxagliptin, trade name
Onglyza) and the joint file process
• Highlighting the problem areas experienced
throughout the application process
• How were these challenges approached and
overcome? Analysing the feedback from the
different regulatory authorities across the globe
Gerald DiDonato, Associate Director, Global
Regulatory Sciences CMC, Bristol Myers Squibb
10.30 Process Understanding: The Key to a
Successful QbD or PAT Implementation.
To properly design quality into your product you
need to understand the relation between functional
requirements and design parameters. At the same
time, the relationship between the design parameters
and process parameters provides the basis to
properly control the manufacturing process used to
realize your product design. QbD combines both aspects,
and holds the promise of reduced time to market and
increased market share. In this session you will:
• See how Design of Experiments (DoE) allows you
to rapidly gain secure knowledge of the two
types of relationships fundamental to QbD.
• Discover how easy to use software packages,
like JMP from SAS, have made DoE a tool for
engineers, not just for statisticians.
• See several real-world examples of the use of
DoE within QbD initiatives in the pharmaceutical
and biotech industry
Dr Per Vase, Senior Specialist, Consulting, NNE
Pharmaplan
10.50 Networking Coffee Break
11.20 Multivariate Statistical Process Control: Moving
Towards Model Based Approaches
• The challenges of capturing, analysing and
monitoring with real time dynamic data
• Understanding why process dynamics and
dynamic multivariate monitoring are important to
assured pharmaceuticals development and
manufacturing
• Analysing the role of dynamics in PAT and QbD
in achieving RTR
• Increasing process understanding using
advanced PAT tools
Professor Julian Morris, Technical Director, CPACT
12.00 Ensuring Efficient QbD and PAT Implementation
PAT and QbD has left the initial phase and the
question that companies face now is how to
implement PAT and QbD in an efficient way rather
than if it is possible.
Umetrics will talk about common themes in projects
which have reached their goals within the given
timeframe and budget including:
• The importance and use of risk analysis, FMEA
• Understanding when and how to employ
multivariate methodology
• The benefits of involving QA at an early phase to
avoid delays in the implementation and
validation phase
Examples range from DoE based development
projects all the way to validated multivariate
on-line installations.
Petter Morree, Director, Online Products,
Umetrics AB
12.45 Networking Lunch Break
14.00 Case Study: Using NIR PAT Application to
Reduce Risk of Scale-Up
This case study will demonstrate how a simple PAT
application reduced the risk to critical Quality
Attributes of scaling up a Unit Dose process
Ayub Khan, Process Technologist, Napp
Pharmaceuticals
14.45 Case Study: Robust Method for the
Determination of Caffeine in Intact Tablets by
Near-infrared Spectroscopy
• Development of a method for the determination
of caffeine in intact tablets
• Effect of the sample size on the predictive
ability of the developed calibration model
• Effect of the sample variance
(variable compression force) on the predictive
ability of the developed calibration model
• Comparison between diffuse reflectance and
diffuse transmittance NIR sampling
Branko Vranic, PhD Student and Teaching Assistant,
Industrial Pharmacy Lab, University of Basel
15.30 Networking Coffee Break
16.00 Gathering Data to Support QbD
• Importance of Product Definition and Process Mapping
• Risk assessment process: Subjective vs. statistical
data, use of FMEA and Cause+Effect Matrix
• Use of measurement systems to gather data
during DoE: Measured vs. Measurement Variance
• Use of PAT to drive process control
Martin Warman, Scientific Fellow, Analytical
Development, Vertex Pharmaceuticals
16.45 Case Study: Application of QbD/PAT on a
Commercial Product: Quality by Re-Design
• The reason why we are trying to implement PAT
will also be shown to be the handling of the
incoming variability in order to deliver predefined
quality each and every time
• The utilisation of Quality Risk Management tools
for finding the Critical Process Parameters. This
includes Fishbone diagrams and FMEA’s
• Why IT and Automation infrastructure are
necessary for using MVDA during manufacturing
• Outlining the need for MVDA in manufacturing
as a confirmation of the established design
space will be described
Dr Hedinn Valthorsson, Manufacturing Manager,
Novartis
17.30 Break-Out Round Table Discussions
Participants will be able to choose between the
different roundtables and spend 45 minutes
discussing the points outlined below before
feeding back to the group
A: The Use of Lean and Six Sigma Initiatives with
PAT when Striving for Operational Excellence
Martin Warman, Scientific Fellow, Analytical
Development, Vertex Pharmaceuticals
B: Successfully Using Quality Risk Management to
Establish CQAs
Zadeo Cimarosti, Manager, Chemical Development,
GlaxoSmithKline Verona, Italy
C: Should You Build in QbD Before or After Proof of
Concept
Michael Schousboe, Senior QbD Manager,
Manufacturing Science and Quality, Novo Nordisk
D: Successfully Creating and Controlling a Secure
Design Space
Dr Barry Gujral MBA, Associate Director, Quality
Engineering, Noven Pharmaceuticals Inc.
E: How to Approach QbD in Biopharmaceuticals
Victor A. Vinci, Director, Bioprocess Operations,
Eli Lilly and Company
18.30 Chairperson’s Closing Remarks and Close of Day One
CALL: +44 (0)20 7368 9300 / 0800 652 2363 FAX: +44 (0)20 7368 9301 EMAIL: enquire@iqpc.co.uk

Conference Day Two: 20th January 2010
08.45 Chairperson’s Opening Remarks
08.55 KEYNOTE PRESENTATION
Case Study: Development of a Monoclonal
Antibody Using QbD: Results from the Industry
Consortium
• Overview of the case study describing
monoclonal antibody development from molecule
design through validation
• Examples of risk assessment strategy and tools used
• Examples of the use of prior platform knowledge
and experimental design for mammalian cell
culture and protein purification
• The analysis leading toward critical quality
attributes (CQAs) and control strategy
• A proposal for design space and lifecycle
management of the process and product
Dr Victor A. Vinci, Director, Bioprocess
Operations, Eli Lilly and Company
09.40 Using QbD Approaches to Enable Development
of Real-Time-Release for a Continuous Drug
Product Process
• Discussion of the QbD risk management
approaches used at Pfizer
• Generation of process understanding and design
space capable of supporting a QbD filing
• Moving from batch processing to continuous
processing for Pharmaceutical drug products
• Implementation of CQV and RTR in
pharmaceutical manufacturing at Pfizer
David Sharp, Senior Principal Scientist, Pfizer
10.20 Business Case on the use of PAT in an Oral
Solid Dosage Pilot Plant
• Outlining a successful PAT implementation in an
Oral Solid Dosage Pilot Plant
• Overcoming some of the key challenges in
putting a PAT strategy into practice
• Discussion of how PAT has contributed towards
cost saving objectives by helping speed up the
development process and shorten the production
time
Patrick Bossuyt, SIPAT Sales Executive, SIEMENS
11.00 Networking Coffee Break
11.30 Case Study: Developing a Successful Change
Management Approach When Implementing
QbD in a Global Company
• How do you approach implementing new
concepts like QbD within the wider business
• Overcoming the challenge of change by
illustrating the benefits and securing buy in.
• Ensuring the business keeps running with both
current and new paradigm’s during implementation
• Preparing for when QbD is part of how we run
the business
Michael Schousboe, Senior QbD Manager,
Manufacturing Science and Quality, Novo Nordisk
12.10 Case Study: Application of QbD in Development:
Building the Control Strategy for Drug
Substance Critical Quality Attributes in the
Manufacturing Process of a Drug Substance
The quality by design approach adopted for the
definition of the control strategy for a drug in
development is described. Details are given on:
• The risk assessment done to identify the
potential quality critical process parameters
• The multivariate and univariate process studies
undertaken to assess the potential quality
critical process parameters
• The specification controls on the input materials
All these elements of control combined together,
allowed the definition of a robust control
strategy with the potential to remove the “endproduct
testing” for some drug substance-CQAs.
Zadeo Cimarosti, Manager, Chemical
Development, GlaxoSmithKline Verona, Italy
12.50 Panel Discussion: Integrating QbD principles
into your Lifecycle Management Programme
• Discussing the benefits of integrating the two
initiatives
• How can this actually be done? What are the
first few steps?
David Sharp, Senior Principal Scientist, Pfizer
Zadeo Cimarosti, Manager, Chemical
Development, GlaxoSmithKline Verona, Italy
Michael Schousboe, Senior QbD Manager,
Manufacturing Science & Quality, Novo Nordisk
Philippe Cappuyns, Pharmaceutical Technology
Director, Janssen Pharmaceutica
13.20 Networking Lunch Break
14.20 Case Study: Developing a Strong Business Case
for QbD Implementation Within a Contract
Manufacturing Company
• Outlining the challenges faced by a CMO
• Discussing the benefits of using QbD in
customer projects
• Highlighting some of the difficulties faced and
how these were overcome
Hans ter Maat, Senior Process Engineer, DSM Biologics
15.00 Case Study: Model-based QbD Development
Integrated in a Product Life Cycle Management
Approach
• The presentation will provide a systematic and
proactive QbD development approach enabling to
meet current ICH Q8, Q9 and Q10 guidelines
• The characteristics of a model-based QbD
development methodology and the resulting
benefits will be highlighted
• The presentation will cover the integration of
QbD into a Product Life Cycle Management
approach and its business value
Philippe Cappuyns, Pharmaceutical Technology
Director, Janssen Pharmaceutica
15.40 Networking Coffee Break
16.10 Case Study: Delivering Robust Manufacturing
Processes Using a Structured Critical Process
Parameter workflow
• Exemplification of the GSK API critical process
parameter workflow
• Workflow essentials: Planning, process
understanding, performance, uncertainty, risk
and control
• Making it happen, adding value
Martin Owen, Manager, GlaxoSmithKline
16.50 Case Study: Implementing PAT and QbD at the
Formulation Stage
• Outline the challenges faced when implementing
these tools earlier in the life cycle
• Discussion of key examples used in transdermal
drugs
• Risk analysis study using these tools
• Comparison of predictive and observed results
Dr Barry Gujral MBA, Associate Director, Quality
Engineering, Noven Pharmaceuticals Inc.
Peter Amanatides, Vice President QA and QC,
Noven Pharmaceuticals Inc.
17.30 Chairperson’s Final Remarks and Close of
Conference
CALL: +44 (0)20 7368 9300 / 0800 652 2363 FAX: +44 (0)20 7368 9301 EMAIL: enquire@iqpc.co.uk

Session Sponsor
Conference Sponsors
Session Sponsor
Session Sponsor
Umetrics – Value from Data. Since 1987, Umetrics' mission
has been to ensure that clients add value to their businesses
through the use of advanced data analysis and experimental
design software and services. Umetrics is the worldwide
recognized leader in the area of multivariate data analysis for
industrial R&D, processes, PAT, QbD and applications.
Umetrics customers have proven many times that the use of
Umetrics technology and services have generated significant
added value by optimizing processes through generation of
reliable information from complex data.
Umetrics offers a complete solution for PAT and QbD
applications in the area of Design of Experiments and
Multivariate Data Analysis. Our offering to industry covers
software products for model building and troubleshooting to
real-time software solutions for process monitoring and
control enabling e.g. RTR – Real Time Release. Training
services, support and projects are important parts of our
offering. Umetrics train more than 1000 scientists and
engineers per year in DoE and MVDA. Umetrics have offices
in US *3, UK, Sweden*2, Singapore and Japan.
Phone: +46 40 664 25 80
Fax: +46 40 664 25 85
Email: info@umetrics.com
Web: www.umetrics.com
Gold Exhibitor
Büchi is a privately held company in the eastern part of
Switzerland. It was founded in 1939 as a glass blowing
workshop. High-tech glass instruments for the use in
chemical laboratories are still one of the core
competencies of Büchi.
In the meantime, Büchi is a world-wide supplier in key
technologies such as evaporation and separation for
research laboratories as well as near infrared
spectroscopy and reference methods for quality control
purposes.
From ergonomic laboratory equipment to the solution of
complex analytical problems in the high-tech sector, Büchi
provides practical support in the chemical laboratory. And
in its own research and development laboratory, Büchi
works constantly on solutions for customer problems in
the areas of Nutrition, Life Sciences and production in the
pharmaceutical and chemistry related industry.
Phone: +41 71 394 63 63
Fax: +41 71 394 65 65
Email: info@buchi.com
Web: www.buchi.com
Siemens Industrial IT develops and implements
software solutions in the domains specification
management (PLM), lab and quality management
(LIMS), MES, PIMS, SCADA, EPMS and metering.
Our offering includes a solution for PAT and QbD in
the pharmaceutical industry, based on SIPAT.
This software solution has been developed in
close cooperation with the FDA to support PAT
implementation efforts and the use of PAT tools in
development and manufacturing.
It is successfully operational at GSK, Merck, Wyeth
and Ferring.
What is SIPAT ?
• SIPAT increases process understanding and
allows continuous process improvement during
manufacturing operations and process
development.
• SIPAT enables monitoring and consolidation of
product quality information, allowing real-time
quality decision making
• SIPAT enables (advanced) process control
whereby it can either focus on specific Unit
operations or it can cover total batch quality to
enable Real-time Product Release.
• SIPAT serves as the common interface for all
PAT tools.
Web: www.swe.siemens.com/belux/sipat/en
JMP is a business unit of SAS Institute, the largest privately held software company with revenues exceeding 2 Bn$. JMP and JMP Genomics are
software products that allow scientists, engineers, and business users to easily get value from their data through “statistical discovery”. JMP has been
under development for 20 years, and is used globally.
Web: www.jmp.com
Testimonials
“Really enjoyed the case examples when a good level of detail was presented. Has been very useful to
understand current status as perceived by industry & network with colleagues.”
Andy Townsend, AstraZeneca
“Very good. Good update and information on current state of QbD & PAT. A good general overview of
what design space is to pharma.”
Steven Brown, Wyeth
Sponsorship Opportunities
Sponsoring the 7th Annual PAT and Quality By Design Forum will deliver:
1. Networking opportunities enabling you to sell directly to, and meet with, key budget holders who had
invested considerable time and money to attend this event and address their business challenges
2. A platform from which to demonstrate your technology and thought-leadership to your target market
3. Brand awareness amongst your target market, keeping your company front of mind for both your
current and prospective clients
Pharma IQ’s 7th Annual PAT and QbD event deals with the current challenges and success stories from within the
pharmaceutical arena, bringing together the key decision makers and innovative minds within the field.
Contact Gal Cohen on +44 (0) 20 7368 9300 or sponsorship@iqpc.co.uk and she will be able to discuss with you
your business goals and how we can help you achieve them
CALL: +44 (0)20 7368 9300 / 0800 652 2363 FAX: +44 (0)20 7368 9301 EMAIL: enquire@iqpc.co.uk

7th Annual PAT and Quality by Design
Two-Day Conference: 19th-20th January 2010 Pre-Conference Workshops: 18th January 2010 Venue: Grand Connaught Rooms, London
REGISTRATION FORM
To speed registration, please provide the priority code located on the mailing label or in the box below.
My registration code is PDFW
B
Please contact our database manager on +44(0) 207 368 9300 or at database@iqpc.co.uk quoting the registration code above to inform
us of any changes or to remove your details.
5 WAYS TO REGISTER
Freephone: 0800 652 2363 or +44 (0)20 7368 9300
Fax: +44 (0)20 7368 9301
Post:
your booking form to
IQPC Ltd. Anchor House, 15-19 Britten
Street,London SW3 3QL
Online:
www.patandqbd.com
Package
Silver Package
Two-Day Conference
+ 2 Workshops
Book and pay before
30 October 2009*
Save £300
£2197 + VAT
Book and pay before
4 December 2009*
Save £200
£2297 + VAT
Standard Price
£2497 + VAT
Email:
TEAM DISCOUNTS
enquire@iqpc.co.uk
IQPC recognises the value of learning in teams. Groups of 3 or more booking at the
same time from the same company receive a 10% discount. 5 or more receive a
15% discount. 7 receive a 20% discount. Only one discount available per person.
Conference No: 11287.004
Bronze Package
Two-Day Conference
+ 1 Workshop**
Conference Only
Two-Day Conference
*Only one discount is applicable per person. In order to qualify for the discounts, payment must be received by the booking
deadlines. Team discounts are applicable to standard prices.
**Please tick. I would like to register for workshop(s):
A Application of PAT and QbD for Biopharmaceuticals
B De-mystifying Regulatory Submission for PAT and QbD
DELEGATE DETAILS
Please photocopy for each additional delegate
DELEGATE 1
Mr Mrs Miss Ms Dr Other
First Name
Family Name
Department
Position
Tel No.
Email
Yes I would like to receive information about products and services via email
Organisation
Nature of business
Address
Postcode Country
Telephone
Fax
Dept. Head Title
Name of person completing form if different from delegate:
Signature
I agree to IQPC’s cancellation, substitution and payment terms
Special dietary requirements: Vegetarian Non-dairy Other (please specify)
Please indicate if you have already registered by Phone Fax Email Web
Please note: if you have not received an acknowledgement before the conference, please call us to confirm your booking.
PAYMENT METHODS
Total price for your Organisation: (Add total of all individuals attending):
Card Number:
VISA MASTERCARD AMEX
Exp. Date: Sec:
Name On Card:
Billing Address (if different from above):
Save £200
£1798 + VAT
Save £100
£1399 + VAT
Save £100
£1898 + VAT
Signature:
£1998 + VAT
£ 1499 + VAT £ 1499 + VAT
City/County/Postcode: Cheque enclosed for: £ (Made payable to IQPC Ltd.)
(Please quote 11287.004 with remittance advice)
IQPC Bank details: HSBC Bank, 67 George Street, Richmond, Surrey, TW9 1HG. United Kingdom.
Sort Code: 40 38 18, Account No: 51304143, IBAN Code: GB59 MIDL 4038 1851 3041 43 Swift Code: MIDLGB2112V
Account name: International Quality & Productivity Centre Ltd.
PAYMENT MUST BE RECEIVED PRIOR TO THE CONFERENCE
VENUE & ACCOMMODATION
VENUE:
Grand Connaught Rooms, 61 - 65 Great Queen Street, Covent Garden, London WC2B
5DA.Tel: +44 (0)20 7405 7811
ACCOMMODATION:
Accommodation is not included in the registration fee. To book nearby
accommodation, for Strand Palace Hotel, 372 The Strand, London, WC2R 0JJ,
please click on to www: https://secure.strandpalacehotel.co.uk/v1web/ When
making online bookings please use Corporate ID GA1. Or call 0207 379 4737,
Always quote booking reference IQPC. Rates start from £95.00 inc vat & Breakfast.
For further nearby accommodation search: www.4cityhotels.com
FREE ONLINE RESOURCES
Our website has changed! You will now find a variety of resources such as articles,
news, podcasts and presentations available online. Many of these features are exclusive
to IQPC so visit www.patandqbd.com today and learn something new for free.
DIGITAL CONFERENCE ON CD ROM
A digital version of the conference proceedings, including all the presentations in
audio format "An excellent service, an invaluable reference tool, easy to access
and easy to store - all in all a top product"
Recent digital conferences available - £599 plus VAT each
Polymorphism and Crystallisation, March 2009
Operational Excellence in Pharmaceutical, Biotech and Medical Devices,
December 2009
Pharmaceutical Amorphous Materials, September 2009
Pharmaceutical Co-Crystals, September 2009
Please send me conference materials indicated above.
I have filled out credit card details below
For further information
Please call: 0207 368 9300 or email: knowledgebank@iqpc.co.uk.
To search IQPC’s archived conference documentation
visit: www.iqpcknowledgebank.com
TERMS & CONDITIONS
PAYMENT TERMS Payment is due in full upon completion and return of the registration form.
Due to limited conference space we advise early registration and payment by credit card to avoid
disappointment. Your registration will not be confirmed until payment is received. Admission to
the conference will be refused if payment has not been received. Payment of invoices by means
other than credit card, or purchase order (UK Plc and Government bodies only) will be subject to a
£49 (plus VAT) processing fee.
CANCELLATION AND SUBSTITUTION POLICY Provided the fee has been paid in full,
substitutions at no extra charge can be made up to 7 business days before the start of the
conference. Cancellations must be received in writing or by fax to +44 (0)20 7368 9301, more
than 7 days before the conference is to be held in order to obtain a full credit for any future
conference. Cancellations received 7 days or less (including the seventh day) prior to the
conference will not be credited. In the event that IQPC cancels an event payments received at
the cancellation date will be credited towards attendance at a future conference, or in the event
of postponement by IQPC, a rescheduled date. Credit notes remain valid for twelve months.
IQPC reserves the right to postpone or cancel an event, to change the location of an event or to
alter the advertised speakers for an event. IQPC is not responsible for any loss or damage as a
result of substitution, alteration, postponement, or cancellation of an event due to causes
beyond its control including without limitation, acts of God, natural disasters, sabotage,
accident, trade or industrial disputes, terrorism, or hostilities. SPEAKER CHANGES
Occasionally it is necessary for reasons beyond our control to alter the content and timing of the
programme or the identity of the speakers
DATA PROTECTION Personal data is gathered in accordance with the Data Protection Act 1998.
Your details may be passed to other companies who wish to communicate with you offers
related to your business activities. If you do not wish to receive these offers, please tick the box
below.
Please do not pass my information to any third party
© IQPC Ltd. 2009 UK VAT is charged at 15% (UK VAT No. GB799225967).